BackgroundCanagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. MethodsThe CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each trial were randomly assigned to receive canagliflozin or placebo and were followed for a mean of 188.2 weeks. The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. ResultsThe mean age of the participants was 63.3 years, 35.8% were women, the mean duration of diabetes was 13.5 years, and 65.6% had a history of cardiovascular disease. The rate of the primary outcome was lower with canagliflozin than with placebo (occurring in 26.9 vs. 31.5 participants per 1000 patient-years; hazard ratio, 0.86; 95% c...

/pdf/canagliflozin-and-cardiovascular-and-renal-events-in-type-2-2rzuupndw9.pdf

Canagliflozin and cardiovascular and renal events in type 2 diabetes

Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium...

https://www.nejm.org/doi/pdf/10.1056/NEJMoa1811744

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

https://minerva-access.unimelb.edu.au/bitstream/handle/11343/238777/Global, regional, and national burden of chronic kidney.pdf

Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) 

Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR) 

ABI
: ankle-brachial index

/pdf/2016-esc-eas-guidelines-for-the-management-of-dyslipidaemias-3oe2qnm09b.pdf

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update.

Validity of registry data: agreement between comorbidities recorded in ANZDATA compared to NSW administrative data

BACKGROUND Renal osteodystrophy leading to fractures in chronic kidney disease (CKD) is associated with significant hospitalization, morbidity, mortality and health care costs. There is a paucity of data on fractures in the CKD population in Australia. AIM To describe the trends and impact of hospitalized fractures in an Australian population of non-dialysis CKD patients. METHODS Retrospective observational data derived using data linkage. Fracture rates, trends in hospital admissions, comorbidity burden and mortality were analysed in a non-dialysis CKD population between 2000 and 2010 in the Australian state of New South Wales. Hospitalized patients with CKD and fractures were compared with CKD patients without fracture. RESULTS A total of 149 839 hospitalized patients with CKD were included, of whom 9898 (6.6%) experienced one or more fractures. Patients with fracture were older, more likely to be female with a higher comorbidity burden than those without. Hospital admissions involving fracture were longer than non-fracture admissions (14.3 vs 5.9 days, P < .0001) and patients were less likely to be discharged home (28.3% vs 80.9%, P < .0001). The 12-month mortality rate was high at 41%. CONCLUSION Australian non-dialysis CKD patients with hospitalized fractures were older, had a greater burden of disease, and have similar rates of fracture and associated mortality compared to international CKD cohorts. Implications of fracture requiring hospitalization are considerable, with longer admissions, greater healthcare costs, lower likelihood of discharge home and significant mortality. As fracture prevention in the CKD population evolves, treatment algorithms should account for those at greatest risk.

Hospitalized fracture rates amongst patients with chronic kidney disease in Australia using data linkage

Buttonhole versus ropeladder cannulation: association with clinical outcomes in a home haemodialysis cohort

http://www.ajkd.org/article/S0272638622005509/pdf

Platform Clinical Trials Within Nephrology-Interpreting the Evidence.

This is an Early Access article. Please select the PDF button, above, to view it.
Be sure to also read the PRO: 10.34067/KID.0006642021 and the COMMENTARY: 10.34067/KID.0008342021


https://kidney360.asnjournals.org/content/kidney360/early/2022/01/20/KID.0007042021.full.pdf

Sradha Kotwal

Papers

Validity of registry data: agreement between comorbidities recorded in ANZDATA compared to NSW administrative data

Hospitalized fracture rates amongst patients with chronic kidney disease in Australia using data linkage

Buttonhole versus ropeladder cannulation: association with clinical outcomes in a home haemodialysis cohort

Platform Clinical Trials Within Nephrology-Interpreting the Evidence.

Should Corticosteroids Be Used to Treat Biopsy-Proven Drug-Induced Acute Interstitial Nephritis?: CON.